The National Trial Lawyers
  • Home
    • Meet Our Team
    • Contact Us
    • Mission & Goals
    • FAQ
  • Webinars
  • News
  • Membership Directory
    • Top 100 Map – Civil Plaintiff
    • Top 100 Map – Criminal Defense
    • Top 40 Under 40 Map – Civil Plaintiff
    • Top 40 Under 40 Map – Criminal Defense
  • Top 100
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Benefits
    • About
    • Top 100 Presidents Message
    • Diplomat
    • Membership Renewal
    • Member Profile Updates
    • Top 100 Badge
  • Top 40
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Top 40 Under 40 Trial Academy Bootcamp
    • Benefits
    • About
    • Top 40 Presidents Message
    • Membership Renewal
    • Member Profile Updates
    • Top 40 Badge
  • Specialty Assoc
    • About
    • Shop
    • Officers
    • Membership Renewal
    • Member Profile Updates
  • Nominate
    • Top 100
    • Top 40
    • Specialty Association
    • Trial Lawyer Hall of Fame
    • Trial Lawyer of the Year
    • Trial Team of the Year
    • America’s Most Influential Trial Lawyer
    • America’s Most Influential Law Firm
    • Lifetime Achievement Award
  • Shop
  • Magazine
    • A-List
  • Education and Networking Agenda
    • Trial Lawyers Summit
    • Top 40 Under 40 Trial Academy Boot Camp
    • Mass Torts Made Perfect
    • The Lanier Trial Academy Master Class 6.0
    • The Business Of Law
    • Webinars
  • Hall of Fame
    • Trial Lawyer Hall of Fame

Justices Signal Uncertainty on Drug Settlements

Posted on March 25, 2013 by Andrew Findley

Thomson Reuters; March 25, 2013

WASHINGTON (Reuters) – U.S. Supreme Court justices on Monday signaled uncertainty over how they would rule on whether brand-name drug companies can settle patent litigation with generic rivals by making deals to keep cheaper products off the market.

Eight justices, lacking the recused Justice Samuel Alito, asked questions that indicated concerns about such deals, but several seemed unsure how courts should approach the matter.

In the deals in question, brand name manufacturers settle litigation by paying generic manufacturers to stay out of the market for a specified period.

U.S. and state regulators say the practice costs consumers, insurers and government billions of dollars annually.

The Federal Trade Commission, which has called the deals “pay for delay,” has fought them in court for more than a decade.

A number of justices on Monday appeared skeptical of the Justice Department’s argument that the deals should be viewed as presumptively unlawful.

Justice Sonia Sotomayor said she had “difficulty understanding” Justice Department lawyer Malcolm Stewart’s argument that “the mere existence” of a payment should change the way courts view a settlement.

But several justices asked questions raising concerns that the deals could be anticompetitive.

Justice Elena Kagan said that in some cases, companies could share monopoly profits “to the detriment of consumers.”

The problem the court appears to face is how to tell lower courts to determine which agreements were lawful and which were not.

Justice Stephen Breyer suggested that the justices should simply tell lower court judges to “keep in mind” that the deals could be anticompetitive.

“In other words, it’s up to the district court,” he said.

It is unclear how many of the justices would support that approach. Justice Antonin Scalia was openly critical, saying it would not tackle “the elephant in the room,” which is the relative strength of the patent being challenged in the case. Justice Anthony Kennedy voiced similar sentiments.

In the case before the court, Solvay Pharmaceuticals Inc, which is now owned by AbbVie, sued generic drugmakers in 2003 to stop cheaper versions of AndroGel, a gel used to treat men with low testosterone.

Solvay paid as much as $30 million annually to Actavis Inc predecessor Watson Pharmaceuticals, Paddock Laboratories Inc and Par Pharmaceutical Cos to help preserve annual profits estimated at $125 million from AndroGel.

Under the deal, the three would stay off the market until 2015. The patent expires in 2020.

The Supreme Court is expected to issue a decision by the end of June.

The case is Federal Trade Commission v. Watson Pharmaceuticals Inc et al, U.S. Supreme Court, No. 12-416.

http://newsandinsight.thomsonreuters.com/Legal/News/2013/03_-_March/Justices_signal_uncertainty_on_drug_settlements/

Posted in Blog, Newsletter

Comments are closed.

Recent Posts

No thumbnail available

Things to Consider When You Sue an Insurance Provider

May 24th, 2022

We are all too acquainted with insurance coverage in our everyday lives. According to Investopedia, everyone should have[Read More...]
The Rochester Diocese Offers a $147 Million Settlement to Sex Abuse Survivors

The Rochester Diocese Offers a $147 Million Settlement to Sex Abuse Survivors

May 23rd, 2022

The Rochester Catholic Diocese is offering a $147 million settlement to sex abuse survivors. This offer comes as a federal ba[Read More...]
Jury Awards $77.5 Million to an Army Veteran in a 3M Earplug Case

Jury Awards $77.5 Million to an Army Veteran in a 3M Earplug Case

May 23rd, 2022

A jury in Pensacola, Fla., federal court on Friday ordered 3M to pay $77.5 million to a U.S. Army veteran who said he suffe[Read More...]
The New Mexico Supreme Court Upholds $165 Million Damage Awards in a Deadly FedEx Crash

The New Mexico Supreme Court Upholds $165 Million Damage Awards in a Deadly FedEx Crash

May 20th, 2022

The New Mexico Supreme Court on Thursday upheld $165 million of jury awards against FedEx in a wrongful-death lawsuit stemmin[Read More...]
Noom Reaches a $56 Million Class Action Settlement Over Its Autorenewal and Cancellation Policy

Noom Reaches a $56 Million Class Action Settlement Over Its Autorenewal and Cancellation Policy

May 20th, 2022

Weight-loss program Noom has agreed to a $56 million settlement to resolve class action claims regarding its autorenewal and [Read More...]

Contact Us | Terms of Use | Privacy Policy

Attorney information and content provided on this website is provided for the benefit of members of The National Trial Lawyers and as a public service by Legal Associations Management, Inc. The website and all data are the property of Legal Associations Management, Inc. Data, including without limitation attorney information and content, on the site may not be mined, sold, or used commercially for any purpose without the explicit written consent of Legal Associations Management, Inc. This site may not be accessed by any automated program for extracting data for any use. By accessing and using the site you agree that you will not develop, support or use software, devices, scripts, robots, or any other means or processes (including crawlers, browser plug-ins and add-ons, or any other technology) to scrape data or otherwise copy profiles and other data. Unauthorized use or attempted unauthorized use of this system may subject you to both civil and criminal penalties.